With key clinical data readouts expected at the end of 2016 and the start of 2017, Corbus Pharmaceuticals Holdings Inc.'s CEO Dr. Yuval Cohen expects the next 12 months to be pivotal for the rare inflammatory disease company. Speaking to Informa Pharma Insights global director of content Mike Ward, Cohen reveals that the company expects to report Phase II data for Resunab, its synthetic endocannabinoid-mimetic compound that binds to the CB2 receptor, in both cystic fibrosis and systemic sclerosis. Phase II data for Resunab in dermatomyositis will be available 1Q 2017.
Video Interview: Corbus Sees 2016 As Pivotal Year
With key clinical data readouts expected at the end of 2016 and the start of 2017, Corbus Pharmaceuticals Holdings Inc.'s CEO Dr. Yuval Cohen expects the next 12 months to be pivotal for the rare inflammatory disease company. Speaking to Informa Pharma Insights global director of content Mike Ward, Cohen reveals that the company expects to report Phase II data for Resunab, its synthetic endocannabinoid-mimetic compound that binds to the CB2 receptor, in both cystic fibrosis and systemic sclerosis. Phase II data for Resunab in dermatomyositis will be available 1Q 2017.
More from Musculoskeletal
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.
• By
Encouraging results in younger children with Duchenne is keeping Regenxbio on track for a potential mid-2026 filing for its gene therapy, RGX-202.
• By
The gene therapy for Duchenne muscular dystrophy passed the blockbuster sales threshold in 2024. Analysts said the drug’s overall risk/benefit profile still appears solid.
• By
Over 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.
More from Therapy Areas
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.